Table 2.
Category (units) | Median (IQR) | Criterion | N | Median survival time (95% CI) | p value | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 75 (75-85) | ||||||||||
<81 | 12 | 224 (79-621) | 0.8 | ||||||||
≥81 | 15 | 220 (62-680) | |||||||||
Sex | Male | 13 | 164 (73-345) | 0.1 | |||||||
Female | 14 | 411 (75-680) | |||||||||
ECOG PS | 0-1 | 20 | 429 (164-680) | 0.00001 | |||||||
≥2 | 7 | 79 (19-89) | |||||||||
FAB diagnosis | AML | 17 | 90 (73-429) | 0.043 | |||||||
MDS RAEB-t | 10 | 393 (130-898) | |||||||||
Karyotype | Complex | 11 | 90 (75-224) | 0.212 | |||||||
Other | 15 | 621 (62-680) | |||||||||
FLT3-ITD mutation | Yes | 1 | 62 (NA-NA) | 0.515 | |||||||
No | 4 | 84 (19-NA) | |||||||||
NCCN risk group | Favorable | 3 | NA | 0.105 | |||||||
Intermediate | 10 | 621 (14-699) | |||||||||
poor | 13 | 90 (73-224) | |||||||||
WT1 mRNA (copy/μgRNA) | 58,000 (27,250-122,500) | <47,000 | 3 | 130 (90-NA) | 0.456 | ||||||
≥47,000 | 5 | 75 (62-NA) | |||||||||
BMI (kg/m2) | 22.37 (19.14-23.78) | <21.53 | 11 | 90 (62-345) | 0.408 | ||||||
≥21.53 | 16 | 429 (90-680) | |||||||||
Azacitidine dose (%) | 89.41 (78.67-94.06) | <89.46 | 14 | 90 (73-345) | 0.013 | ||||||
≥89.46 | 13 | 429 (90-699) | |||||||||
WBC (/μL) | 3,400 (1,850-7,600) | <5,600 | 17 | 224 (84-638) | 0.202 | ||||||
≥5,600 | 10 | 130 (14-NA) | |||||||||
Neutro (/μL) | 930 (585.5-1,938) | <1,727 | 18 | 393 (84-638) | 0.597 | ||||||
≥1,727 | 9 | 130 (14-345) | |||||||||
PB blast (%) | 10 (3.25-38.75) | <3 | 6 | 422.5 (19-NA) | 0.639 | ||||||
≥3 | 21 | 220 (84-429) | |||||||||
Hb (g/dL) | 7.9 (6.35-9.2) | <7.8 | 12 | 147 (73-224) | 0.144 | ||||||
≥7.8 | 15 | 429 (75-699) | |||||||||
RDW (%) | 15.95 (14.55-17.575) | <14.5 | 6 | 668.5 (89-NA) | 0.031 | ||||||
≥14.5 | 20 | 220 (75-393) | |||||||||
Ret (%) | 2.4 (0.9-4.65) | <2 | 10 | 90 (14-NA) | 0.326 | ||||||
≥2 | 17 | 393 (89-638) | |||||||||
Plt (/μL) | 27,000 (18,000-65,500) | <27,000 | 12 | 90 (19-345) | 0.006 | ||||||
≥27,000 | 15 | 621 (84-699) | |||||||||
LDH (U/L) | 279 (225-458) | <279 | 13 | 429 (75-699) | 0.099 | ||||||
≥279 | 14 | 164 (79-393) | |||||||||
Ferritin (ng/mL) | 549 (302.45-815) | <560 | 10 | 284.5 (62-638) | 0.599 | ||||||
≥560 | 10 | 130 (19-NA) | |||||||||
CRP (mg/dL) | 0.52 (0.19-1.95) | <0.35 | 10 | 491.5 (14-898) | 0.093 | ||||||
≥0.35 | 17 | 175 (79-429) | |||||||||
Bone marrow cellularity | Hypercellular | 5 | 429 (626-NA) | 0.58 | |||||||
Normocellular | 10 | 130 (14-638) | |||||||||
Hypocellular | 8 | 422.5 (73-898) | |||||||||
NCC (104/μL) | 5.6 (3.1-14.5) | <16.8 | 18 | 393 (89-638) | 0.301 | ||||||
≥16.8 | 5 | 84 (14-NA) | |||||||||
M:E ratio | 1.32 (0.7-3.13) | <0.88 | 8 | 411 (62-NA) | 0.717 | ||||||
≥0.88 | 16 | 224 (89-680) | |||||||||
MegK (/μL) | 13 (0-50) | <19 | 12 | 638 (89-898) | 0.019 | ||||||
≥19 | 11 | 90 (62-429) | |||||||||
BM blast (%) | 39.4 (25.6-50.6) | <40.4 | 13 | 393 (220-680) | 0.07 | ||||||
≥40.4 | 11 | 84 (62-638) | |||||||||
BM mono (%) | 2.9 (0.6-4.55) | <1.6 | 8 | 621 (14-699) | 0.553 | ||||||
≥1.6 | 16 | 224 (79-429) |
IQR: interquartile range, N: number, CI: confidence interval, ECOG PS: Eastern Cooperative Oncology Group performance status, FAB: French-American-British, AML: acute myeloid leukemia, MDS RAEB-t: myelodysplastic syndromes refractory anemia with excess blasts in transformation, NA: not applicable, NCCN: National Comprehensive Cancer Network, WT1: Wilms tumor 1, BMI: body mass index, WBC: white blood cell count, PB blast: percentage of blasts in white blood cells, Hb: hemoglobin, RDW: red cell distribution width, Ret: percentage of reticulocytes, Plt: platelet count, LDH: lactate dehydrogenase, CRP: C-reactive protein, NCC: nucleated cell count in bone marrow, M:E ratio: ratio of maturing myeloid cells to erythroid cells in bone marrow, MegK: megakaryocyte count in bone marrow, BM blast: percentage of blasts in bone marrow, BM mono: percentage of monocytes in bone marrow
For continuous variables, the criterion was determined based on the maximum value of the Youden index for the receiver operating characteristic curve with the dependent variable being survival at 1 year. Univariate analyses were conducted with log-rank testing.